Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody

$Lane 1: HepG2 Cells; Lane 2: Hela Cells; Probed with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: HepG2 Cells; Lane 2: Hela Cells; Probed with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$Lane 1: Mouse Kidney; Lane 2: PC-12 Cells; Probed with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Mouse Kidney; Lane 2: PC-12 Cells; Probed with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Stomach Cancer tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Stomach Cancer tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Hippocampus tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Hippocampus tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Brain tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Brain tissue incubated with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Flow cytometric analysis of Hela cells with Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody (bsm-54110R) at 1:100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

Applications

WB
FCM
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-54110R
Product Name	Pyruvate Dehydrogenase E1 beta subunit (10A1) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein within C-terminal human Pyruvate Dehydrogenase E1 beta subunit
Clonality	Monoclonal
Clone #	10A1
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at 4C for up to 2 weeks. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.
Target
Gene ID	5162
Swiss Prot	P11177
Synonyms	Pyruvate dehydrogenase E1 component subunit beta, mitochondrial; PDHE1-B; PDHB; PHE1B; PDHBD; PDHE1B.
Background	The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO. It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). Defects in PDHB are a cause of pyruvate dehydrogenase E1 component deficiency (PDHE1 deficiency). PDHE1 deficiency is the most common enzyme defect in patients with primary lactic acidosis. It is associated with variable clinical phenotypes ranging from neonatal death to prolonged survival complicated by developmental delay, seizures, ataxia, apnea, and in some cases to an X-linked form of Leigh syndrome (LS) (Leigh encephalomyelopathy).
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200